Regorafenib Trial Meets Primary Endpoint; Overall Survival Improved by 29 Percent
Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial
ETP-ALL May Be Linked To Acute Myeloid Leukemia
CyberKnife Delivers 100 Percent PFS at 18.3 Month Followup
BRCA1 and BRCA2 Mutations Linked To Higher Survival
Matted Lymph Nodes Can Predict Survival Rate, Spread of Disease
Chromosomal Abnormalities Predict Long Median Survival
Analysis Shows No Mortality Benefit From Regular PSA Screening
Ovarian Cancer Symptom Indices May Need to be Re-Evaluated
Self-Collected Pap Smear Tests Could Advance HPV Screening
Trials Approved by NCI CTEP For the Month of January
Palmetto Establishes Coverage For Thyroid Genomic Test
FDA Approves Inlyta Pill For Renal Cell Carcinoma
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- A new working group will conduct site visits and advise NCAB and NCI director on cancer center grants
- Michael Bishop, Nobel-winning cancer researcher, dies at 90
- At a jam-packed NCAB meeting, cancer vaccines and site visits take center stage
- Roy Herbst named director at Dartmouth Cancer Center
- In the era of immunotherapy, response rate alone fails to predict true patient benefit
Regulators must adapt
